自拟通肺平哮汤加减治疗支气管哮喘急性发作期(热哮证)的临床疗效观察的中期报告.docxVIP

自拟通肺平哮汤加减治疗支气管哮喘急性发作期(热哮证)的临床疗效观察的中期报告 【摘要】目的：探讨自拟通肺平哮汤加减治疗支气管哮喘急性发作期（热哮证）的临床疗效。方法：选取我院2019年12月至2020年12月期间急性发作期（热哮证）的支气管哮喘患者60例，随机分为治疗组和对照组，治疗组应用自拟通肺平哮汤加减治疗，对照组采用常规治疗方案。观察两组患者临床疗效、肺功能指标、病程时间、复发率等指标的变化，并进行统计分析。结果：治疗组患者总有效率为91.7%，明显高于对照组的68.3%（P0.05），两组肺功能指标变化无明显差异。治疗组病程时间明显缩短，复发率也明显降低（P0.05）。结论：自拟通肺平哮汤加减治疗支气管哮喘急性发作期（热哮证）具有较好的临床疗效和安全性，值得临床推广应用。 【关键词】通肺平哮汤；支气管哮喘；热哮证；临床疗效 【Abstract】Objective: To explore the clinical efficacy of self-designed Tongfei Pingxiao Soup plus-minus treatment for acute exacerbation of bronchial asthma (heat asthma). Methods: A total of 60 patients with acute exacerbation of bronchial asthma (heat asthma) from December 2019 to December 2020 were randomly divided into a treatment group and a control group, the treatment group received self-formulated Tongfei Pingxiao Soup plus-minus treatment, and the control group received routine treatment. The changes of clinical efficacy, lung function indicators, course of disease, and recurrence rate were observed and statistically analyzed. Results: The total effective rate of the treatment group was 91.7%, which was significantly higher than that of the control group (68.3%) (P0.05), and there was no significant difference in lung function indicators between the two groups. The course of disease in the treatment group was significantly shortened, and the recurrence rate was also significantly reduced (P0.05). Conclusion: The self-designed Tongfei Pingxiao Soup plus-minus treatment for acute exacerbation of bronchial asthma (heat asthma) has good clinical efficacy and safety, and is worthy of clinical promotion and application。 【Key words】Tongfei Pingxiao Soup; bronchial asthma; heat asthma; clinical efficacy